PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8317554-7 1993 Enzyme induction with paraquat, adriamycin, or bleomycin was inhibitable by neutralizing antibody to interleukin-1 and tumor necrosis factor, suggesting that the inductions observed with these three drugs are due to the distal mediators, interleukin-1 or tumor necrosis factor released from the cells. Doxorubicin 32-42 interleukin 1 alpha Homo sapiens 238-276 20599921-2 2010 After finding a close connection between Interleukin-1 family and doxorubicin-induced cardiotoxicity, we assumed that recombinant human interleukin-1 receptor antagonist (rhIL-1Ra), the natural antagonist of interleukin-1, might have a protective role in doxorubicin-induced cardiotoxicity. Doxorubicin 255-266 interleukin 1 alpha Homo sapiens 136-149 25275022-0 2014 Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere. Doxorubicin 95-106 interleukin 1 alpha Homo sapiens 36-45 25275022-6 2014 The expression of IL-1alpha and VEGF was up-regulated in PDT-treated cells, either alone or in combination with doxorubicin or taxotere. Doxorubicin 112-123 interleukin 1 alpha Homo sapiens 18-27 20599921-0 2010 Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Doxorubicin 80-91 interleukin 1 alpha Homo sapiens 18-31 20599921-2 2010 After finding a close connection between Interleukin-1 family and doxorubicin-induced cardiotoxicity, we assumed that recombinant human interleukin-1 receptor antagonist (rhIL-1Ra), the natural antagonist of interleukin-1, might have a protective role in doxorubicin-induced cardiotoxicity. Doxorubicin 66-77 interleukin 1 alpha Homo sapiens 136-149 12415617-8 2002 IL-1 alpha also increased the sensitivity of these cells to doxorubicin but not to cisplatin or topotecan. Doxorubicin 60-71 interleukin 1 alpha Homo sapiens 0-10 8512591-1 1993 Interleukin-1 alpha (IL-1 alpha) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH:OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. Doxorubicin 179-190 interleukin 1 alpha Homo sapiens 21-31 8512591-1 1993 Interleukin-1 alpha (IL-1 alpha) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH:OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. Doxorubicin 192-195 interleukin 1 alpha Homo sapiens 0-19 8512591-1 1993 Interleukin-1 alpha (IL-1 alpha) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH:OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. Doxorubicin 192-195 interleukin 1 alpha Homo sapiens 21-31 8512591-6 1993 DOX was found to significantly increase IL-1 alpha accumulation by NIH:OVCAR-3 cells after long-term (48 hr) exposure to the cytokine at 37 degrees, which might be due to increased nonspecific fluid phase uptake or to interference with cytokine degradation and/or release processes. Doxorubicin 0-3 interleukin 1 alpha Homo sapiens 40-50 8453624-0 1993 Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice. Doxorubicin 63-74 interleukin 1 alpha Homo sapiens 40-59 8453624-1 1993 Experiments were performed to determine whether treatment with recombinant human IL-1 alpha (rhuIL-1 alpha) would protect C3H mice from the toxic effects of the widely used chemotherapeutic agent, doxorubicin (DXR). Doxorubicin 197-208 interleukin 1 alpha Homo sapiens 81-91 1292755-1 1992 We have investigated the antiproliferative effects of recombinant human interleukin-1 alpha (IL-1) combined with the cytotoxic antitumor drug doxorubicin against A375 human melanoma IL-1-sensitive (C6) and IL-1-resistant (C5) clonal cell lines. Doxorubicin 142-153 interleukin 1 alpha Homo sapiens 182-186 7803193-2 1993 Pretreatment with recombinant human interleukin-1 beta (IL-1) protected normal BALB/c mice from the lethal effect adriamycin (ADM) of related to dose and frequency of administration. Doxorubicin 114-124 interleukin 1 alpha Homo sapiens 56-60 7803193-2 1993 Pretreatment with recombinant human interleukin-1 beta (IL-1) protected normal BALB/c mice from the lethal effect adriamycin (ADM) of related to dose and frequency of administration. Doxorubicin 126-129 interleukin 1 alpha Homo sapiens 56-60 7803193-5 1993 It appears that the chemoprotection mechanism of IL-1 lies in the prevention of cardiotoxicity due to ADM-induced free radicals. Doxorubicin 102-105 interleukin 1 alpha Homo sapiens 49-53 1292755-1 1992 We have investigated the antiproliferative effects of recombinant human interleukin-1 alpha (IL-1) combined with the cytotoxic antitumor drug doxorubicin against A375 human melanoma IL-1-sensitive (C6) and IL-1-resistant (C5) clonal cell lines. Doxorubicin 142-153 interleukin 1 alpha Homo sapiens 182-186 1292755-4 1992 The strongest synergism occurred when C6 cells were exposed to IL-1 prior to doxorubicin, and when C5 cells were pretreated with doxorubicin for 6 hr prior to IL-1 additions. Doxorubicin 77-88 interleukin 1 alpha Homo sapiens 63-67 1292755-4 1992 The strongest synergism occurred when C6 cells were exposed to IL-1 prior to doxorubicin, and when C5 cells were pretreated with doxorubicin for 6 hr prior to IL-1 additions. Doxorubicin 129-140 interleukin 1 alpha Homo sapiens 159-163 1292755-6 1992 Doxorubicin treatment enhanced the binding and internalization of [125I]IL-1 after 24 and 48 hr at 37 degrees C, but IL-1 binding to cells incubated on ice was increased only marginally by doxorubicin pretreatment. Doxorubicin 0-11 interleukin 1 alpha Homo sapiens 72-76 1292755-6 1992 Doxorubicin treatment enhanced the binding and internalization of [125I]IL-1 after 24 and 48 hr at 37 degrees C, but IL-1 binding to cells incubated on ice was increased only marginally by doxorubicin pretreatment. Doxorubicin 189-200 interleukin 1 alpha Homo sapiens 117-121 1292755-8 1992 A recombinant protein IL-1 receptor antagonist that binds to both the 80 kDa type I and the 65 kDa type II IL-1 receptors, blocked the cytostatic effects of IL-1 and abrogated the synergism with doxorubicin. Doxorubicin 195-206 interleukin 1 alpha Homo sapiens 22-26 34547383-12 2021 Meanwhile, DOX further increased the elevation of plasma IL-6, IL-1beta and TNF-alpha induced by DMM and obviously reduced the expression of chondrocyte differentiation-related markers, including collagen type II a1 (Col2A1), collagen type X alpha 1 (Col10A1), and aggrecan. Doxorubicin 11-14 interleukin 1 alpha Homo sapiens 63-71 34120620-9 2021 DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-alpha and IL-1beta. Doxorubicin 0-3 interleukin 1 alpha Homo sapiens 270-278 35551917-7 2022 Moreover, we identified Doxo-induced senescence to be mediated by the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, a key player of the immune innate system capable of releasing interleukin (IL)-1beta. Doxorubicin 24-28 interleukin 1 alpha Homo sapiens 204-226 35551917-8 2022 In fact, IL-1beta itself mimicked the stimulatory action of Doxo on both NLRP3 activation and cellular senescence, while the pharmacological blockade of IL-1 receptors markedly attenuated the pro-senescence effects of Doxo. Doxorubicin 60-64 interleukin 1 alpha Homo sapiens 9-17 34145895-8 2021 The increased malondialdehyde (MDA) and Interleukin-1beta (IL-1beta), and decreased superoxide dismutase (SOD) were observed in the DOX group, while tVNS significantly prevented these changes. Doxorubicin 132-135 interleukin 1 alpha Homo sapiens 59-67 2565969-0 1989 Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro. Doxorubicin 0-11 interleukin 1 alpha Homo sapiens 37-50 2565969-1 1989 Since interleukin 1 (IL-1) induces the transcriptional synthesis of enzymes responsible for cartilage resorption it was decided to examine the effects of the antitumour drug, doxorubicin, a DNA transcriptional inhibitor, on alpha IL-1-induced cartilage--resorption in-vitro. Doxorubicin 175-186 interleukin 1 alpha Homo sapiens 230-234 2565969-3 1989 Fine structure of the chondrocytes was preserved by the doxorubicin treatment with IL-1 in contrast to the extensive cellular destruction evident in cartilage treated with IL-1 alone. Doxorubicin 56-67 interleukin 1 alpha Homo sapiens 83-87 2565969-4 1989 [14C]doxorubicin was bound to cartilage proteoglycans, and this effect was promoted by treatment of the cartilage with IL-1. Doxorubicin 5-16 interleukin 1 alpha Homo sapiens 119-123 33952842-11 2021 In addition, DOX induced the mitochondrial damage and increased the expression of Interleukin-1 (IL-1) via stress-activated protein kinases (SAPK)/ c-Jun NH-2termial kinase (JNK). Doxorubicin 13-16 interleukin 1 alpha Homo sapiens 82-95 33952842-11 2021 In addition, DOX induced the mitochondrial damage and increased the expression of Interleukin-1 (IL-1) via stress-activated protein kinases (SAPK)/ c-Jun NH-2termial kinase (JNK). Doxorubicin 13-16 interleukin 1 alpha Homo sapiens 97-101